Atuka provides contract research and consultancy services for the biopharmaceutical industry with world-leading expertise in Parkinson’s disease and related neurological conditions. We provide cutting-edge, rodent and non-human primate models (toxin and molecular pathology-driven) to evaluate efficacy and target engagement over a comprehensive range of symptomatic, motor (e.g. parkinsonism and dyskinesia), non-motor (e.g. cognition and impulse control) and disease-modification assays. Atuka also offers medicinal chemistry, DMPK and in-vivo imaging services to aid development of novel therapeutics.
Certara is the global leader in advancing modern, efficient drug development. We provide proven modeling & simulation, regulatory and real world value assessment software and services. In partnership with our clients, we help reduce clinical trial burden, accelerate regulatory approval and increase patient access to medicines. 90% of all novel drugs approved by FDA have used Certara software and/or services.
Axol, the hiPSC-Derived cell culture specialists, produce high quality human cell products for the range of neuroscience research needs. Our expertise includes reprogramming cells to iPSCs and then differentiating to various cell types, supplying differentiated cells derived from healthy donors and patients of specific disease backgrounds, such as Alzheimer's, Huntington's and Parkinson's. We also take cells provided by customers (primary or iPSC), reprogram when necessary and differentiate to order. Axol holds the necessary licenses required to do iPSC work.
Rho, a contract research organization (CRO) located in Durham, NC, provides a full range of services across the entire drug development process. For more than 30 years, Rho has been a trusted partner to leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, innovative technologies, and therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience.
Proprietary MultiBrain® technology powers NSA’s simultaneous sectioning, and expertly-guided staining, of up to 40 neuronal tissues in one MultiBrain® block, achieving uniform processing across all 40 tissues. Implementing NSA’s Large Format™ technology enables sectioning and staining of intact human brain hemispheres and yields comprehensive, uninterrupted vantage and analysis of the ultimate target. Coupling these mass production technologies with cutting-edge digital image capture and hosting, along with contemporary analysis tools increasingly powered by AI, rapidly produces rich data, and dramatically reduces R&D times.
Olink provides a protein biomarker discovery service that delivers unparalleled data quality in a high-multiplex. Specifically, from 1ul of plasma or CSF we will deliver 92 highly validated protein measurements, and from 15ul we can deliver 1161 validated datapoints. We enable precision medicine initiatives for clients looking for disease prognostic, pharmacodynamic, or response-signature biomarkers.
QPS is a global CRO providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. QPS is known for proven quality standards, technical expertise, a flexible approach to research, high client satisfaction and turnkey laboratories and facilities. Our profound expertise in neuroscience and two decades of experience in contract research results in a sustainable advantage for our customers.
Gubra is a privately-held Danish biotech company delivering scientific counselling, CRO services, and projects for co-development in four main focus areas: obesity, diabetes, NASH and diabetic complications. Gubra experts cover various pre-clinical disciplines spanning in vivo pharmacology, molecular pharmacology, histology, 3D imaging, stereology, NGS, bioinformatics and ex vivo assays. With a scientific background in neuroanatomy, stereology and imaging, co-founder Jacob Jelsing, has led several preclinical studies in neurodegenerative diseases.